Details for Patent: 7,982,049
✉ Email this page to a colleague
Which drugs does patent 7,982,049 protect, and when does it expire?
Patent 7,982,049 protects MYRBETRIQ GRANULES and MYRBETRIQ and is included in two NDAs.
Protection for MYRBETRIQ GRANULES has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has twenty-seven patent family members in sixteen countries.
Summary for Patent: 7,982,049
Title: | .alpha.-form or .beta.-form crystal of acetanilide derivative |
Abstract: | To provide novel crystals useful as an ingredient for the production of a diabetes remedy. The invention is concerned with .alpha.-form crystal and .beta.-form crystal of (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]a- cetanilide. The .alpha.-form crystal does not exhibit hygroscopicity and has stability such that it can be used as a medicine, and is useful for mass synthesis in the industrial production. The .beta.-form crystal does not relatively exhibit hygroscopicity and is also useful as a production intermediate of the .alpha.-form crystal. |
Inventor(s): | Kawazoe; Souichirou (Takahagi, JP), Sakamoto; Kenichirou (Takahagi, JP), Awamura; Yuji (Tsukuba, JP), Maruyama; Tatsuya (Tsukuba, JP), Suzuki; Takayuki (Tsukuba, JP), Onda; Kenichi (Tsukuba, JP), Takasu; Toshiyuki (Tsukuba, JP) |
Assignee: | Astellas Pharma Inc. (Tokyo, JP) |
Application Number: | 12/007,653 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,982,049 |
Patent Claim Types: see list of patent claims | Composition; Compound; Use; Formulation; Dosage form; |
Drugs Protected by US Patent 7,982,049
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Apgdi | MYRBETRIQ GRANULES | mirabegron | FOR SUSPENSION, EXTENDED RELEASE;ORAL | 213801-001 | Mar 25, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Apgdi | MYRBETRIQ | mirabegron | TABLET, EXTENDED RELEASE;ORAL | 202611-001 | Jun 28, 2012 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Apgdi | MYRBETRIQ | mirabegron | TABLET, EXTENDED RELEASE;ORAL | 202611-002 | Jun 28, 2012 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 7,982,049
Foriegn Application Priority Data | ||
Foreign Country | Foreign Patent Number | Foreign Patent Date |
Japan | 2001-332914 | Oct 30, 2001 |
International Family Members for US Patent 7,982,049
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2002344419 | ⤷ Try a Trial | |||
Brazil | 0213570 | ⤷ Try a Trial | |||
Brazil | PI0213570 | ⤷ Try a Trial | |||
Canada | 2464068 | ⤷ Try a Trial | |||
China | 1243740 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |